JP2005519885A - 第ｘａ因子阻害剤としてのピロリジン−２−オン - Google Patents

第ｘａ因子阻害剤としてのピロリジン−２−オン Download PDF

Info

Publication number
JP2005519885A
JP2005519885A JP2003554642A JP2003554642A JP2005519885A JP 2005519885 A JP2005519885 A JP 2005519885A JP 2003554642 A JP2003554642 A JP 2003554642A JP 2003554642 A JP2003554642 A JP 2003554642A JP 2005519885 A JP2005519885 A JP 2005519885A
Authority
JP
Japan
Prior art keywords
alkyl
oxopyrrolidin
halogen
mass spectrum
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003554642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519885A5 (https=
Inventor
アラン・デイビッド・ボースウィック
チュエン・チャン
ヘンリー・アンダーソン・ケリー
ナイジェル・ポール・キング
サバス・クリーンソース
アンドリュー・マクマートリー・メイソン
アイバン・レオ・ピント
デレク・ローランド・ポラード
シュテファン・ゼンガー
ジータ・プンジャバイ・シャー
ナイジェル・スティーブン・ワトソン
ロバート・ジョン・ヤング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005519885A publication Critical patent/JP2005519885A/ja
Publication of JP2005519885A5 publication Critical patent/JP2005519885A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2003554642A 2001-12-21 2002-12-20 第ｘａ因子阻害剤としてのピロリジン−２−オン Pending JP2005519885A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130705.7A GB0130705D0 (en) 2001-12-21 2001-12-21 Chemical compounds
PCT/EP2002/014826 WO2003053925A1 (en) 2001-12-21 2002-12-20 Pyrrolidine-2-ones as factor xa inhibitors

Publications (2)

Publication Number Publication Date
JP2005519885A true JP2005519885A (ja) 2005-07-07
JP2005519885A5 JP2005519885A5 (https=) 2006-01-26

Family

ID=9928210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003554642A Pending JP2005519885A (ja) 2001-12-21 2002-12-20 第ｘａ因子阻害剤としてのピロリジン−２−オン

Country Status (23)

Country Link
US (1) US20050059726A1 (https=)
EP (1) EP1456172A1 (https=)
JP (1) JP2005519885A (https=)
KR (1) KR20040072666A (https=)
CN (1) CN100364971C (https=)
AR (1) AR037928A1 (https=)
AU (1) AU2002366747A1 (https=)
BR (1) BR0215200A (https=)
CA (1) CA2471461A1 (https=)
CO (1) CO5590896A2 (https=)
GB (1) GB0130705D0 (https=)
HU (1) HUP0500137A2 (https=)
IL (1) IL162454A0 (https=)
IS (1) IS7316A (https=)
MX (1) MXPA04006139A (https=)
MY (1) MY141579A (https=)
NO (1) NO20042990L (https=)
NZ (1) NZ533129A (https=)
PL (1) PL371008A1 (https=)
RU (1) RU2318807C2 (https=)
TW (1) TWI262075B (https=)
WO (1) WO2003053925A1 (https=)
ZA (1) ZA200404147B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538202A (ja) * 2005-02-25 2008-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な坑血栓性置換ピロリジノン、これらの製造及び薬物の形態のこれらの使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
GB0314299D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
EP1641752A1 (en) 2003-06-19 2006-04-05 Glaxo Group Limited 3- sulfonylamino- pyrrolidine- 2- one derivatives as inhibitors of factor xa
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
US7169795B2 (en) 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7381728B2 (en) 2004-07-28 2008-06-03 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
DE102004062544A1 (de) 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
EP1869010A1 (en) * 2005-04-11 2007-12-26 Glaxo Group Limited 3-sulfonylamino-pyrrolidine-2-one derivatives as factor xa inhibitors
WO2006137527A1 (ja) 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
DK1921077T3 (en) 2005-08-02 2017-10-23 Kyowa Hakko Kirin Co Ltd Means for treating and / or preventing sleep disorders
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
JP2009517351A (ja) * 2005-11-24 2009-04-30 グラクソ グループ リミテッド 化学物質
DK2012839T3 (da) 2006-04-07 2012-04-10 Bactiguard Ab Hidtil ukendte antimikrobielle substrater og anvendelser deraf
KR20090053923A (ko) * 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
CN116712596A (zh) * 2023-05-30 2023-09-08 北京福爱乐科技发展有限公司 一种用于体内创面喷涂型医用胶及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202344A (en) * 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
SI9520044B (sl) * 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5731315A (en) * 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
AU4064597A (en) * 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
GB9715894D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538202A (ja) * 2005-02-25 2008-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な坑血栓性置換ピロリジノン、これらの製造及び薬物の形態のこれらの使用

Also Published As

Publication number Publication date
WO2003053925A1 (en) 2003-07-03
US20050059726A1 (en) 2005-03-17
MXPA04006139A (es) 2004-11-01
TWI262075B (en) 2006-09-21
IL162454A0 (en) 2005-11-20
GB0130705D0 (en) 2002-02-06
NZ533129A (en) 2006-12-22
EP1456172A1 (en) 2004-09-15
CA2471461A1 (en) 2003-07-03
KR20040072666A (ko) 2004-08-18
CN100364971C (zh) 2008-01-30
AU2002366747A1 (en) 2003-07-09
IS7316A (is) 2004-06-16
RU2004122427A (ru) 2006-01-20
HUP0500137A2 (en) 2006-02-28
NO20042990L (no) 2004-09-20
AR037928A1 (es) 2004-12-22
CO5590896A2 (es) 2005-12-30
CN1620434A (zh) 2005-05-25
BR0215200A (pt) 2004-10-13
PL371008A1 (en) 2005-06-13
ZA200404147B (en) 2005-06-21
MY141579A (en) 2010-05-14
RU2318807C2 (ru) 2008-03-10
TW200306178A (en) 2003-11-16

Similar Documents

Publication Publication Date Title
US10093683B2 (en) Factor XIa inhibitors
RU2318807C2 (ru) Пирролидин-2-оны в качестве ингибиторов фактора ха
CN101374835B (zh) 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法
JP2022515879A (ja) 複素環式化合物、中間体、その製造方法及び応用 本願は、出願日が２０１８年１２月２９日の中国特許出願ｃｎ ２０１８１１６４２３１９、出願日が２０１９年０５月２４日の中国特許出願ｃｎ２０１９１０４４０２１４．３及び出願日が２０１９年１０月２４日の中国特許出願ｃｎ２０１９１１０１６１５８．７に基づいて優先権を主張する。また、上記中国特許出願の全文は本願に援用される。
WO2022042591A1 (zh) 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
AU2004226281B2 (en) Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses
KR20090010098A (ko) Ｘａ 인자 저해제
MX2014007269A (es) Derivados de piridinona y pirimidinona como inhibidores del factor xia.
BRPI0620010A2 (pt) compostos ánalogos de arilpropionamida, arilacrilamida, arilpropinamida, ou arilmetiluréia, processo para sua preparação, composição farmacêutica e uso dos mesmos
EP2114928A2 (en) Thiophene carboxamides as factor xa inhibitors
EP2809652B1 (en) Isoquinoline and naphthyridine derivatives
KR20180064382A (ko) Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도
GB2497806A (en) Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
JP2007523927A (ja) Ｘａ因子阻害剤としてのピロール誘導体
EP3350176B1 (en) Novel oxazole derivatives that inhibit syk
WO2006109846A1 (ja) トリアゾール誘導体およびその用途
CZ20033325A3 (cs) Deriváty pyrrolidinu jako inhibitory faktoru Xa
SK9162001A3 (en) Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
AU2009312427B2 (en) Pyrrolidines
CN101341129B (zh) 作为因子xia抑制剂的芳基丙酰胺，芳基丙烯酰胺，芳基丙炔酰胺，或芳基甲基脲类似物
TW202509019A (zh) Sarm1調節子、其製劑及用途
JP2005521641A (ja) 第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド
JP2006527731A (ja) Ｘａ因子阻害剤としてのピロリジン−２−オン
AU2004245187B2 (en) Aroyl semicarbazide derivatives against thromboembolic diseases
JP2006527729A (ja) 急性血管疾患の治療用のｘａ因子阻害剤としての１−フェニル−２−オキソ−３−スルホニルアミノ−ピロリジン誘導体および関連化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091201